March 14 (Reuters) - Nyxoah SA NYXH.BR :
* BETTER SLEEP ACHIEVES PRIMARY ENDPOINT ACROSS ALL PATIENT
COHORTS
* FIRST CLINICAL DATA DEMONSTRATING EFFECTIVENESS OF HGNS TO
TREAT
CCC PATIENTS
* PRIMARY ENDPOINT OF AHI4 REDUCTIONS FOR POPULATION, CCC
COHORT,
NON-CCC COHORT AT 6 MONTHS; REPORTS 60%+ RESPONDER RATES FOR
THREE COHORTS
* EXCEEDS 70% MEAN REDUCTION IN AHI4 AMONG RESPONDERS IN
BOTH CCC
AND NON-CCC COHORTS
Source text for Eikon: ID:nGNEccWJFP
Further company coverage: NYXH.BR
((reuters.briefs@thomsonreuters.com;))